September 2026 brought major procedural movement in mass-tort litigation through expert-evidence hearings, settlement-administration orders, and new federal safety notices. A mass tort is a group of individual injury claims that share alleged harm from the same product or exposure. The most immediate developments affect how cases may be proved, administered, or investigated. They do not turn every agency warning or court filing into an individual recovery.
Table of Contents
- The federal MDL landscape remains the starting point
- GLP-1 litigation turns on expert proof
- Depo-Provera orders focus on settlement administration
- PFAS cases face an expert-evidence and records deadline
- FDA notices create practical health questions
The federal MDL landscape remains the starting point
The Judicial Panel on Multidistrict Litigation's active-MDL report provides the federal docket baseline for tracking coordinated mass-tort cases in September 2026, according to the U.S. JPML's September 1 report.
A pending MDL does not necessarily accept a new direct filing. In the C-Qur mesh litigation, direct filings into MDL 2753 stopped February 23, 2026. A prospective claimant should confirm the proper court and filing route before assuming that a federal MDL remains available.
GLP-1 litigation turns on expert proof
The GLP-1 gastrointestinal-injury MDL held a September 14–18 Rule 702/Daubert hearing on cross-cutting issues. The cases involve alleged gastrointestinal injuries tied to Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro; Novo Nordisk and Eli Lilly deny the claims, according to the Eastern District of Pennsylvania MDL page.
A Daubert hearing tests whether expert testimony may be admitted. That makes it especially important in product-liability cases, where expert opinions often connect a drug or product to an alleged injury.
Depo-Provera orders focus on settlement administration
The Depo-Provera MDL entered three September 4 orders appointing a lien-resolution master, a qualified-settlement-fund administrator, and a supplemental-compensation-fund allocation master. Those appointments build infrastructure for resolving medical liens, holding settlement funds, and allocating supplemental compensation. They signal work on distribution mechanics rather than a new jury verdict.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
PFAS cases face an expert-evidence and records deadline
In the AFFF/PFAS MDL, parties must respond to Rule 702 challenges to thyroid- and liver-cancer general-causation experts by September 4, with replies due October 2. The District of South Carolina's case-management order places expert admissibility at the center of the next litigation phase. PFAS reporting may also expand available information.
EPA says covered manufacturers and importers generally must report PFAS production, use, disposal, exposure, and hazard data by October 13, 2026, under its TSCA reporting guidance. EPA's draft PFOA/PFOS biosolids guidance had a September 4 comment deadline. Its recommendations are voluntary, have no legal force, and cannot be relied on in litigation against the United States.
FDA notices create practical health questions
FDA added its strongest labeling warning to Injectafer on September 1 for symptomatic hypophosphatemia, or low phosphate levels. The agency recommends phosphate monitoring for at-risk patients and for repeat treatment within three months, according to the FDA's Injectafer safety communication.
FDA also added Kybella warnings after reviewing adverse-event reports and medical literature. Serious neuromuscular events may occur when Kybella is injected outside submental fat, and nodules or masses may persist and require medical intervention.
- Keep treatment dates, product names, records, and invoices.
- Ask a treating clinician about symptoms or repeat-treatment monitoring.
- Preserve photos and communications when an injection-site problem is involved.
- Check court-specific filing rules before acting on a possible claim.
You Might Also Like
- What Is New With Pharmaceutical Lawsuits Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- What Is New With Medical Device Lawsuits Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways
- What Is New With Legal Glossary Mass Tort Litigation in September 2026? Latest court filings and agency notices and Key Takeaways